Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Several other equities analysts also recently issued reports on CTSO. EF Hutton Acquisition Co. I raised Cytosorbents to a strong-buy rating in a research report on Monday, July 29th. HC Wainwright reissued a neutral rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Wednesday, August 14th.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $1.12 on Wednesday. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $2.15. The company has a market cap of $60.82 million, a PE ratio of -1.90 and a beta of 0.51. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.71 and a current ratio of 2.12. The business has a 50-day simple moving average of $1.14 and a two-hundred day simple moving average of $0.99.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. The company had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $9.73 million. During the same period last year, the business earned ($0.14) EPS. As a group, equities analysts expect that Cytosorbents will post -0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Key Client Fiduciary Advisors LLC boosted its holdings in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares during the last quarter. CM Management LLC boosted its stake in shares of Cytosorbents by 98.8% in the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after buying an additional 410,000 shares during the last quarter. Avenir Corp grew its holdings in Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the period. Sargent Investment Group LLC raised its position in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Finally, Atomi Financial Group Inc. acquired a new position in Cytosorbents in the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.